ReviewBlood2017
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.
Review in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 306 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
306 citing papers in PubMed.
- Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.Blood advances · 2022Trial
- Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study.Orphanet journal of rare diseases · 2021Trial
- KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm.Blood advances · 2026Article
- A 25-year evolution of systemic mastocytosis to mast cell leukemia: Cutaneous clues.JAAD case reports · 2026Article
- Article
- Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.Journal of hematology & oncology · 2026Article
- Gallbladder Involvement in Aggressive Systemic Mastocytosis.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- The Characteristics of 924 Cutaneous Mast Cell Tumours in Dogs ≤ 3 Years of Age-With a Short Literature Review of Feline, Equine, and Human Proliferative Mast Cell Disorders.Veterinary sciences · 2026Article
- Article
- Low BMD is uncommon in pediatric mastocytosis: a DEXA- based cohort study.European journal of pediatrics · 2026Article
- Clinical Spectrum of Drug Hypersensitivity Reactions in Systemic Mastocytosis: Drug-Induced Anaphylaxis as a Unique Clinical Presentation.Medicina (Kaunas, Lithuania) · 2026Article
- Emerging Insights into Hereditary Alpha-Tryptasemia in the Context of Mast Cell Disorders: A Greek Case Series.Journal of personalized medicine · 2026Article
- Management Strategy for Anaphylaxis in a Patient With Suspected or Confirmed Mastocytosis: A Case Report.The American journal of case reports · 2026Article
- Mast Cell Mediators and Their Diagnostic Utility in Clonal and Nonclonal Mast Cell Activation Disorders.Current allergy and asthma reports · 2026Review
- Prolonged IL-33 Exposure Switches the Secreted Mast Cell Cytokine Profile From Pro-Inflammatory to Pro-Tolerant.Allergy · 2026Article
- Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.Current allergy and asthma reports · 2026Review
- Case Report: Experience of a rare case of primary acute mast cell leukemia with FGFR1 gene rearrangement.Frontiers in oncology · 2026Article
- Allogeneic Transplantation in Advanced Systemic Mastocytosis: A Single-Center Case Series Highlighting Gastrointestinal Toxicity and GvHD Risk.Mediterranean journal of hematology and infectious diseases · 2026Article
- Is histamine intolerance a treatable subtype of fibromyalgia? evidence and clinical implications-narrative review.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Molecular characterization of pediatric mastocytosis revealed different somatic mutations with uncertain prognostic value.Frontiers in cell and developmental biology · 2026Article
246 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Over the past few years, substantial advances have been made in understanding the pathogenesis, evolution, and complexity of mast cell neoplasms. New diagnostic and prognostic parameters and novel therapeutic targets with demonstrable clinical impact have been identified. Several of these new markers, molecular targets, and therapeutic approaches have been validated and translated into clinical practice. At the same time, the classification of mastocytosis and related diagnostic criteria have been refined and updated by the consensus group and the World Health Organization (WHO). As a result, more specific therapies tailored toward prognostic subgroups of patients have been developed. Emerging treatment concepts use drugs directed against KIT and other relevant targets in neoplastic mast cells and will hopefully receive recognition by health authorities in the near future. This article provides an overview of recent developments in the field, with emphasis on the updated WHO classification, refined criteria, additional prognostic parameters, and novel therapeutic approaches. Based on these emerging concepts, the prognosis, quality of life, and survival of patients with advanced mastocytosis are expected to improve in the coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.